INmune Bio adds two directors with rare-disease and business-development backgrounds
The company appointed R. Duane Clark II and James Sapirstein to its board on September 8, 2026, as Ebstrocel nears potential commercialization.
SEC filing
Latest
3 stories
Monday, September 14
Wednesday, August 12
Onconetix files S-1 to register 100 million shares tied to Series F preferred stock
The Cincinnati-based oncology company registered shares for resale after a $30.25 million private placement, disclosing a going concern warning and a pending Realbotix share exchange.
SEC filing
Wednesday, July 29
Onconetix arranges $30.25 million PIPE financing and $750 million equity line
The company entered agreements on July 28, 2026 for a Series F preferred stock sale and a large committed equity facility, both disclosed in an 8-K filed with the SEC.
SEC filing